Special Issue "Immune Checkpoint Inhibitors in Cancer Therapy: State of the Art and Future Perspectives"
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 47376
Interests: epithelial to mesenchymal transition; cancer stem cells; immune checkpoints; triple negative breast cancer
Interests: colorectal cancer; gastric cancer; ovarian cancer
In this Special Issue, we aim to collect original studies, meta-analyses, clinical studies, reviews, and letters investigating recent advances in knowledge around immune checkpoint inhibition strategies in various cancers.
Immune checkpoint inhibitor (ICI)-based immunotherapy represents one of the most significant therapeutic innovations in the oncologic landscape to date. The recent introduction of ICIs, which mainly targets cytotoxic T lymphocyte–associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and its ligand (PD-L1), not only benefits patients with metastatic melanoma but also those with historically less responsive tumor types. However, these ICIs have their own distinctive adverse events, which are collectively named “immune-related adverse events”. The biological mechanisms contributing to these immune-related adverse events are still poorly understood and warrant further studies.
Clinical studies have shown that only a subset of cancer patients respond to ICI therapies. Better understanding of the tumor microenvironmental and immune status through biomarkers and other biological mechanisms may help to decipher the reasons behind differential responses and the development of resistance to ICI therapies. Moreover, the initial clinical trials of ICI combinations have yielded more promising results than ICI monotherapy alone. The number of checkpoints identified has been increasing in recent times. Biomarker identification and personalized treatment aimed at minimizing toxicity while maintaining therapeutic efficacy remain unmet medical needs and thus merit further research and clinical efforts.
Dr. Aparna Jayachandran
Prof. Dr. George Kannourakis
Dr. Prashanth Prithviraj
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune checkpoint inhibitors
- drug resistance
- immune related adverse events
- personalized treatment